Lamivudine/3TC reverse transcriptase inhibitor data

BCHXF presented results of a Phase II trial of Lamivudine in patients with chronic hepatitis B infection, showing an inhibitory effect on virus replication as reflected in lower serum viral DNA.

The European trial in 48 patients showed a more pronounced effect at doses of 20 mg a day or more. Data from 38 of the patients was presented at the British Society of Gastroenterology meeting. ...